Study identifier:D2550C00004
ClinicalTrials.gov identifier:NCT01937338
EudraCT identifier:N/A
CTIS identifier:N/A
A Double blind, Randomised, Placebo-controlled, 2-period, Cross-over Study in Healthy Volunteers to Investigate the Effects of a Single Dose of Inhaled AZD7624 on White Blood Cells and Inflammatory Markers in Induced Sputum and Blood after Oral Inhalation of 45,000 Endotoxin Units Lipopolysaccharide (LPS)
LPS Challenge, Neutrophils
Phase 1
Yes
AZD7624, Placebo
All
60
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Nov 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD7624 | Drug: AZD7624 nebuliser solution; 20 mg/mL for inhalation |
Placebo Comparator: Placebo | Drug: Placebo nebuliser solution for inhalation |